Patents by Inventor Michelle Campbell

Michelle Campbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11928095
    Abstract: Example embodiments relate to a system to generate and cause display of a specially configured graphical user interface to receive and present collections of images. According to certain example embodiments, an image analysis system: receives an image file from a client device; generates a hash value based on the image file; performs a comparison of the hash value with a list that comprises a collection of hash values; identifies a match to the hash value among the collection of hash values; assigns a label to the image file in response to identifying the match among the collection of image files from the list; and indexes the image file at a memory location identified by the label assigned to the image file.
    Type: Grant
    Filed: September 9, 2022
    Date of Patent: March 12, 2024
    Assignee: Palantir Technologies Inc.
    Inventors: Michael Stein, Adam Campbell, Alicia Monfre, Angela Muller, Enoch Hsiao, Lucas Ray, Matthew Brady, Michelle Brown, Paul Lisker
  • Publication number: 20220098296
    Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Application
    Filed: July 27, 2021
    Publication date: March 31, 2022
    Inventors: Michael Otto BARDROFF, Barbara BRANNETTI, Emma Michelle CAMPBELL, Beate DIEFENBACH-STREIBER, Adina EBERTH, Christian Carsten Silverster KUNZ, Sylwia MARSHALL, Jean-Michel Rene RONDEAU, Jean-Marc Alfred SCHLAEPPI, Gino Anselmus VAN HEEKE
  • Patent number: 11111293
    Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: September 7, 2021
    Assignee: NOVARTIS AG
    Inventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
  • Patent number: 10683471
    Abstract: A neutral or acidic automatic dishwashing detergent composition including inorganic bleach, enzymes and a cleaning agent selected from the group consisting of cleaning surfactants, soil suspending polymers and mixtures thereof and from 0.01% to 5% by weight of the composition of a perfume and wherein the composition has a cleaning index of at least 60 and a care index of at least 4 as defined herein.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 16, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Philip Frank Souter, Alan Thomas Brooker, Lindsay Suzanne Bewick, Lynn Michelle Campbell
  • Publication number: 20190085068
    Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Application
    Filed: August 24, 2018
    Publication date: March 21, 2019
    Applicant: NOVARTIS AG
    Inventors: Michael Otto BARDROFF, Barbara BRANNETTI, Emma Michelle CAMPBELL, Beate DIEFENBACH-STREIBER, Adina EBERTH, Christian Carsten Silverster KUNZ, Sylwia MARSHALL, Jean-Michel Rene RONDEAU, Jean-Marc Alfred SCHLAEPPI, Gino Anselmus VAN HEEKE
  • Patent number: 10081677
    Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: September 25, 2018
    Assignee: NOVARTIS AG
    Inventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
  • Publication number: 20170175044
    Abstract: A neutral or acidic automatic dishwashing detergent composition including inorganic bleach, enzymes and a cleaning agent selected from the group consisting of cleaning surfactants, soil suspending polymers and mixtures thereof and from 0.01% to 5% by weight of the composition of a perfume and wherein the composition has a cleaning index of at least 60 and a care index of at least 4 as defined herein.
    Type: Application
    Filed: November 30, 2016
    Publication date: June 22, 2017
    Inventors: Philip Frank SOUTER, Alan Thomas BROOKER, Lindsay Suzanne BEWICK, Lynn Michelle CAMPBELL
  • Patent number: 9650438
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: May 16, 2017
    Assignee: Novartis AG
    Inventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Publication number: 20170101467
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: February 24, 2015
    Publication date: April 13, 2017
    Applicant: Novartis AG
    Inventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Publication number: 20160376361
    Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Application
    Filed: May 25, 2016
    Publication date: December 29, 2016
    Applicant: NOVARTIS AG
    Inventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
  • Patent number: 9376489
    Abstract: Interleukin 18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: June 28, 2016
    Assignee: Novartis AG
    Inventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silvester Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
  • Patent number: D966484
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: October 11, 2022
    Assignee: DSS PureAir, Inc.
    Inventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell
  • Patent number: D967380
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: October 18, 2022
    Assignee: DSS PureAir, Inc.
    Inventors: Neil Campbell, Iyam Lynch, Michelle Campbell
  • Patent number: D967381
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: October 18, 2022
    Assignee: DSS PureAir, Inc.
    Inventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell
  • Patent number: D967382
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: October 18, 2022
    Assignee: DSS PureAir, Inc.
    Inventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell
  • Patent number: D967383
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: October 18, 2022
    Assignee: DSS PureAir, Inc.
    Inventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell
  • Patent number: D979032
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: February 21, 2023
    Assignee: DSS, Inc.
    Inventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell
  • Patent number: D1010088
    Type: Grant
    Filed: October 7, 2022
    Date of Patent: January 2, 2024
    Assignee: DSS PureAir, Inc
    Inventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell
  • Patent number: D1010089
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: January 2, 2024
    Assignee: DSS PureAir, Inc.
    Inventors: Neil Campbell, Iyam Lynch, Michelle Campbell
  • Patent number: D1010090
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: January 2, 2024
    Assignee: DSS PureAir, LLC
    Inventors: Neil J. Campbell, Iyam Lynch, Michelle Campbell